We look forward to expanding our presence in New York and are proud to say that we can now offer almost every customer in the state a lower cost option compared to the incumbent provider," said Ambit
Energy CEO and co-founder Jere W.
In the study, Ambit
scientists profiled 38 different kinase inhibitors, including approved drugs and preclinical compounds, against a panel of 317 kinases.
This next step in our relationship joins Bristol-Myers Squibb's premier chemistry with Ambit
's unparalleled kinase screening and discovery technology to accelerate the advancement of high quality drug candidates into clinical development," said Scott Salka, Chief Executive Officer of Ambit
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Kinases are extremely important targets for a wide range of diseases, including cancer, inflammation, and metabolic and neurological disorders," said Scott Salka, chief executive officer of Ambit
Using KinomeScan, Ambit
engineered AC220 to potently target FLT3, KIT, CSF1R/FMS, RET and PDGFRa/b kinases, all of which are validated drug targets.
Elms, who has served as a director on the Ambit
board since 2001, where he acted as chairman from July 2005 to November 2009.
has developed novel visualization and analysis tools to make the best use of data generated by KinomeScan.
Ever since I headed up Syrrx prior to its acquisition by Takeda, I've been a big believer in the importance of high-throughput drug discovery tools, and Ambit
has one of the most exciting screening platforms I've seen," said Dr.
This is an exciting time to join the Ambit
management team as we continue to forge partnerships with leading pharmaceutical companies and prepare to begin clinical trials with our own compounds," said Kelly.
SAN FRANCISCO, March 30, 2015 /PRNewswire/ -- Sunrun, the largest dedicated residential solar company in the United States, today announced a partnership with Ambit
Energy, a leading retail energy provider of electricity and natural gas in deregulated states, to offer affordable home solar to new and existing Ambit
customers in California, New Jersey, New York and Massachusetts.
Daiichi Sankyo Company, Limited and Ambit
Biosciences Corporation (hereinafter, Ambit
Biosciences) today announced the results of Daiichi Sankyo s tender offer to purchase all of the outstanding shares of Ambit
Biosciences common stock for $15.